-
XOMA CEO Engle Resigns
Wednesday, August 31, 2011 - 4:36pm | 79XOMA Ltd. (Nasdaq: XOMA) announced today Steve Engle has chosen to resign from his positions as Chief Executive Officer, President and Chairman of the Board, effective August 31, 2011. As a result, the Board has appointed John Varian, a current Board member, as interim Chief Executive Officer and W...
-
Onyx Pharmaceuticals Appoints Dr. Helen Torley as Chief Commercial Officer
Wednesday, August 31, 2011 - 4:06pm | 37Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it has appointed Helen Torley, M.B. Ch. B., M.R.C.P., as Executive Vice President and Chief Commercial Officer.
-
Afternoon Movers; Monster Worldwide Down 5.35%
Wednesday, August 31, 2011 - 3:34pm | 111DISH Network (NASDAQ: DISH) +5.40% - hearing reports saying that the company may consider selling itself after building spectrum. Human Genome Sciences (NASDAQ: HGSI) -5.00% after Citigroup lowers the company's PT to $15. Standard Pacific (NYSE: SPF) -5.17% on low volume. bebe stores (NASDAQ:...
-
Morning Market Movers
Wednesday, August 31, 2011 - 9:50am | 112D. Medical Industries Ltd (NASDAQ: DMED) shares surged 23.89% to $3.06 at 9:45 am. DMED reported its Q2 sales of NIS 523 thousand (US$ 153 thousand). ADA-ES Inc (NASDAQ: ADES) shares advanced 21.83% to $16.74. ADA-ES agreed to pay $33 million to settle Norit International dispute. Cell...
-
MLV Comments On New H5N1 Bird Flu Vaccine
Wednesday, August 31, 2011 - 9:36am | 136McNicoll, Lewis & Vlak has published a research report on Novavax (NASDAQ: NVAX) after recent evidence showed signs of a new emerging variant of the H5N1 Bird Flu. In the report, MLV writes, "Recent reports of a new emerging variant of pandemic bird flu, H5N1-2.3.2.1, resistant to currently...
-
UPDATE: Citi Lowers Price Target On Human Genome Sciences To $15
Wednesday, August 31, 2011 - 8:58am | 81According to Citi, Human Genome Sciences (NASDAQ: HGSI) price target is lowered to $15. Citi said that it is lowering its Benlysta ests due to a slower U.S. launch and more modest peak sales potential, it is lowering its TP to $15 (-$11) based on DCF. “This is based on our IMS sales tracker and...
-
Dendreon Appoints John E. Osborn EVP & General Counsel
Wednesday, August 31, 2011 - 8:56am | 276Dendreon Corporation (NASDAQ: DNDN) today announced the appointment of John E. Osborn as executive vice president, general counsel and corporate secretary, effective August 30. Mr. Osborn has more than 25 years' experience in law, business, and public policy. He previously served as general...
-
Aeterna Zentaris Announces Completion of Interim Analysis by Data Safety Monitoring Board for the Phase 3 Study of Perifosine for the Treatment of Refractory Advanced Colorectal Cancer
Wednesday, August 31, 2011 - 8:35am | 171Aeterna Zentaris Inc. (NASDAQ: AEZS) today announced that the independent Data Safety Monitoring Board for the pivotal Phase 3 X-PECT study of perifosine in patients with refractory advanced colorectal cancer has completed a pre-specified interim analysis for safety and futility. The DSMB has...
-
Keryx Biopharmaceuticals Announces Completion of Interim Analysis by Data Safety Monitoring Board for the Phase 3 Study of KRX-0401 for the Treatment of Refractory Advanced Colorectal Cancer
Wednesday, August 31, 2011 - 8:31am | 97Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) announced today that the independent Data Safety Monitoring Board (DSMB) for the Company's pivotal Phase 3 X-PECT study of KRX-0401 (perifosine) in patients with refractory advanced colorectal cancer has completed a pre-specified interim analysis for...
-
Brean Murray Initiating Coverage On Onyx Pharmaceuticals, Inc. (NASDAQ)
Wednesday, August 31, 2011 - 7:47am | 41Brean Murray Carret & Co. is out with a research report on Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) and it is initiating coverage with a Hold rating. Shares of ONXX closed at $33.69 yesterday, down 1 cent.
-
Citigroup Lowers PT On Human Genome Sciences To $15
Wednesday, August 31, 2011 - 6:06am | 27Citigroup has lowered the price target on Human Genome Sciences (NASDAQ: HGSI) from $26 to $15 and maintains its Hold rating.
-
McNicoll, Lewis & Vlak Maintains Aeterna Zentaris Buy, PT
Tuesday, August 30, 2011 - 3:41pm | 147McNicoll, Lewis & Vlak maintained its Aeterna Zentaris (NASDAQ: AEZS) Buy rating and $5.50 price target in a research report published today. In the report, McNicoll, Lewis & Vlak states, "This morning, Æterna Zentaris (AEZS; Last close: $1.89) announced positive top-line results of its...
-
Notable Put Options Activity in Alexion Pharmaceuticals
Tuesday, August 30, 2011 - 1:38pm | 115Shares of Alexion Pharmaceuticals (NASDAQ: ALXN) are higher on the session by 0.16%, currently trading at $57.11. The stock has been moving largely higher over the past three months and is currently trading above the 50-day moving average. Options traders are focusing on puts today. A short while...
-
Notable Call Options Activity in Sangamo BioSciences
Tuesday, August 30, 2011 - 11:56am | 145Shares of Sangamo BioSciences (NASDAQ: SGMO) are higher on the session by 3.73%, currently trading at $5.28. The stock has been moving largely lower over the past three months and is currently trading below the 50-day moving average. Options traders are focusing on calls today. A short while ago...
-
Notable Call Options Activity in BioCryst Pharmaceuticals
Tuesday, August 30, 2011 - 11:39am | 97Shares of BioCryst Pharmaceuticals (NASDAQ: BCRX) are higher on the session by 9.65%, currently trading at $3.41. The stock has been moving largely higher over the past three weeks and is currently trading above the 50-day moving average. Options traders are focusing on calls today. A short while...